Stocklytics score rationale: value 60, quality 30, growth 50.
Financials
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
0
1413000
8353000
15000000
78000000
383000000
112000000
117000000
258000000
247000000
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1…
Forecast
Consensus Buy from 18 analysts. Average price target $38.80, +106.3% versus the current price. Low $23.00. High $45.00.
Analysts have an average 12-month price target of $38.80 for Arcus Biosciences (RCUS), 106.3% above the current price of $18.81. Of 18 analysts covering the stock, 15 rate it Buy or Strong Buy, 3 Hold, and 0 Sell or Strong Sell, giving a consensus of Buy.
Forecasts are third-party estimates and often wrong. They are not investment advice.
RCUS price target
12-month price target
Low
$23.00
Average
$38.80
High
$45.00
The average is 106.3% above the current price of $18.81.
Is Arcus Biosciences a buy or sell?
Of 18 analysts, 15 rate Arcus Biosciences Buy or Strong Buy, 3 Hold, and 0 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.
The Stocklytics Score for RCUS is 47 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.
RCUS forecast FAQs
What is the RCUS price target?
$38.80 average, with a published range of $23.00 to $45.00.
Is Arcus Biosciences a buy or sell?
The consensus is Buy from 18 analysts. This is not a recommendation.
What is the Arcus Biosciences stock forecast for 2026?
Analysts' average EPS estimate for 2026 on file is -3.56. The average revenue estimate is $73.15 million.
What will RCUS be worth in 2030?
No reliable forecast exists that far out.
When is Arcus Biosciences's next earnings report?
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.